The travel vaccine market is expected to grow from US$ 267.56 million in 2021 to US$ 524.88 million by 2028; it is estimated to grow at a CAGR of 10.1% from 2022 to 2028.
Travel vaccines, also called travel immunizations, are shots travelers get before visiting certain areas of the world that help protect them from developing serious illnesses. Vaccinations work by exposing the body to a weakened/dead germ or part of a germ of the disease. These vaccines are recommended to protect against diseases endemic to the country of origin or destination. It is intended to protect travelers and prevent disease spread within or between countries. In many cases, countries require proof of vaccination for travelers wishing to enter or exit the country.
Travelling and tourism have become an integral part of the human lifestyle. It has added a change in the ongoing routine of people and offered several opportunities to explore different cultures, traditions, spiritualism, rural and ethnic tourism, and wellness and health holidays worldwide. Travelling outside the country requires immunization as a safety and precautionary measure to avoid spreading infections. Various countries have policies to protect their citizens from travel-associated infections. For instance, in the UK, National Health Service (NHS) organizes routine immunization or vaccination schedule for its citizens. If a person travels outside the UK, they must get vaccinated to prevent infectious diseases such as hepatitis A, typhoid, and yellow fever. With ~40 million visitors in 2017, the UK is among the most well-liked foreign travel destinations. Although the UK is renowned for its unpredictable weather, the winters and summers are generally temperate, albeit occasionally damp. The UK recognizes Covaxin as a reliable COVID-19 travel vaccination. This indicates that those immunized with Covaxin, one of the two main COVID-19 vaccines, will not have to separate themselves once they arrive in England. After experiencing a significant annual decline in 2020 due to the COVID-19 pandemic, Statista reports that the number of foreign tourists arriving in Europe increased by ~20% in 2021 compared to 2020.
Based on product, the UK travel vaccines market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. The others segment holds held the largest market share in 2021. However, the meningococcal vaccines segment is expected to register the highest CAGR during the forecast period. The others segment primarily consists of the human papillomavirus vaccine, Zika virus vaccine, DPT (tetanus/diphtheria/pertussis), yellow fever, typhoid, Japanese encephalitis, measles, mumps and rubella, rabies, polio, influenza, varicella and shingles, cholera, and others. Typhoid is caused by Salmonella typhi and is common UK, 21.5 million cases are registered every year with 216,500 deaths every year. Influenza is a common viral infection in Europe, influenza activity appeared to decrease. Influenza A(H3N2) predominated. Cause by Vibrio cholerae, cholera is an acute diarrheal illness which affects 1.3 to 4 million people and causes 21,000-143,000 deaths every year UK. Vaccines protects against the HPV group of more than 200 related viruses. Out of these, 200 related viruses more than 40 are spread through direct sexual contact. Two types of HPV can cause genital warts, while more than 24 types can cause certain types of cancers such as, cervical, anal, oropharyngeal, among others. In the US, three HPV vaccines have been licensed for usage – Gardasil, Gardasil 6, and Cervarix. While travel advisories have no recommendations around HPV vaccinations, travelers of all kind prefer getting vaccinated, especially those who travel regularly to regions with high prevalence of HPV.
Based on application, the travel vaccine market is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment is likely to account for the largest share of the market. The market for this segment is expected to grow at the fastest CAGR of 10.4% during 2021–2028. Outbound travel is the act of traveling outside of the home country for leisure, business, or other purposes. Many people travel internationally for business purposes. The number of visits abroad from the UK dropped sharply in 2020 over the previous year due to the COVID-19 pandemic, then fell further in 2021. That year, holidays accounted for the best outbound visits, with roughly 8.9 million trips made for this purpose. However, the number of vacations abroad only accounted for 15% of the holiday trips made in 2019. Overall, the number of visits abroad from the UK was approximately 19 million in 2021. Spending on trips abroad by residents of the UK increased by 12% in 2021 over the previous year, after dropping sharply in 2020 due to the pandemic. Overall, the outbound tourism expenditure within the UK amounted to roughly US$ 20.7 billion in 2021, rising from US$ 18.73 billion in 2020 but remaining way below pre-pandemic levels. While the outbound expenditure slightly recovered in 2021, the number of visits abroad from the UK declined further compared to the first year of the crisis. In 2022, in a Travel Leaders Group survey, 24% of Americans stated they planned to travel to Europe. Additionally, it is expected that the tourist arrivals are expected to increase steadily in regions such as Asia and Europe.
A few key primary and secondary sources referred to while preparing the report on the travel vaccine market are the World Health Organization (WHO), UK Health Security Agency, and the CDC.
Increasing Travel and Tourism Driving UK Travel Vaccines Market.
According to our latest study on "UK Travel Vaccines Market Forecast to 2028 – COVID-19 Impact and Country Analysis – by Product and Application," the market is expected to reach US$ 524.88 million by 2028 from US$ 267.56 million in 2021. The market is estimated to grow at a CAGR of 10.1% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments.
Travel and tourism have become an integral part of the human lifestyle. Traveling has added a change in the ongoing routine of people and offered several opportunities to explore different cultures, traditions, spiritualism, rural and ethnic tourism, and wellness and health holidays worldwide. Traveling outside the country requires immunization as a safety and precautionary measure to avoid spreading infections. Various countries have policies to protect their citizens from travel-associated infections. For instance, in the UK, National Health Service (NHS) organizes routine immunization or vaccination schedule for its citizens. If a person travels outside the UK, they must get vaccinated to prevent infectious diseases such as hepatitis A, typhoid, and yellow fever. With ~40 million visitors in 2017, the UK is among the most well-liked foreign travel destinations. Although the UK is renowned for its unpredictable weather, the winters and summers are generally temperate, albeit occasionally damp. The UK recognizes Covaxin as a reliable COVID-19 travel vaccination. This indicates that those immunized with Covaxin, one of the two main COVID-19 vaccines, will not have to separate themselves once they arrive in England. After experiencing a significant annual decline in 2020 due to the COVID-19 pandemic, Statista reports that the number of foreign tourists arriving in Europe increased by ~20% in 2021 compared to 2020. Although they peaked in 2019 at 745 million, foreign visitor arrivals were still far below pre-pandemic levels in 2021, registering ~287 million foreign visitors. UK was the leading country in terms of total international visitor arrivals worldwide in 2021. VisitBritain, A national tourism organization, reports that the UK received 11.1 million foreign visitors in 2020, a 73% decrease from the number of visitors in 2019. Inbound travel to the UK in 2020 comprised 11% from North America, 72% from Europe, and 17% from other nations. Thus, the increasing travel and tourism are driving the demand for the UK travel vaccines.
Based on product, the market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. The others segment held the largest share of the market in 2021. However, the meningococcal vaccines segment is anticipated to register the highest CAGR of 10.5% during the forecast period. Based on application, the UK travel vaccines market is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held a larger market share. Moreover, the outbound travel segment is expected to register a higher CAGR of 10.4% from 2021 to 2028.
Prominent players in the UK travel vaccines market implement inorganic strategies such as mergers, acquisitions, and partnerships. For instance, in December 2021, Emergent BioSolutions Inc. announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. The current version of the influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. These factors are expected to provide lucrative opportunities for the overall UK travel vaccines market growth during the forecast period.
GlaxoSmithKline plc.; Merck & Co., Inc.; Sanofi; Novartis AG; Pfizer Inc.; Dynavax Technologies; Emergent BioSolutions Inc.; Abbott; Seqirus; and Valneva SE are among the key players operating in the UK travel vaccines market.
The report segments the UK travel vaccines market as follows:
Based on product, the UK travel vaccines market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. Based on application, the UK travel vaccines market is segmented into domestic travel and outbound travel.
